These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30664937)

  • 21. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induced Pluripotent Stem Cell Technology: A Paradigm Shift in Medical Science for Drug Screening and Disease Modeling.
    Nair M; Sandhu SS; Sharma AK
    Curr Med Chem; 2017; 24(39):4368-4398. PubMed ID: 28748763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Promise and Perils of Compound Discovery Screening with Inducible Pluripotent Cell-Derived Neurons.
    Sharlow ER; Koseoglu MM; Bloom GS; Lazo JS
    Assay Drug Dev Technol; 2020; 18(2):97-103. PubMed ID: 31095406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induced pluripotent stem cells for disease modeling, cell therapy and drug discovery in genetic autonomic disorders: a review.
    Saito-Diaz K; Zeltner N
    Clin Auton Res; 2019 Aug; 29(4):367-384. PubMed ID: 30631982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetically-modified human pluripotent stem cells: new hopes for the understanding and the treatment of neurological diseases?
    Nedelec S; Onteniente B; Peschanski M; Martinat C
    Curr Gene Ther; 2013 Apr; 13(2):111-9. PubMed ID: 23444870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induced pluripotent stem cells for modeling of pediatric neurological disorders.
    Jang J; Quan Z; Yum YJ; Song HS; Paek S; Kang HC
    Biotechnol J; 2014 Jul; 9(7):871-81. PubMed ID: 24838856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling.
    Beghini DG; Kasai-Brunswick TH; Henriques-Pons A
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induced pluripotent stem cells: a new revolution for clinical neurology?
    Mattis VB; Svendsen CN
    Lancet Neurol; 2011 Apr; 10(4):383-94. PubMed ID: 21435601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neural Progenitor Cell Derivation Methodologies for Drug Discovery Applications.
    Porterfield V
    Assay Drug Dev Technol; 2020; 18(2):89-95. PubMed ID: 31090435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using Human iPSC-Derived Peripheral Nervous System Disease Models for Drug Discovery.
    Gao Y
    Handb Exp Pharmacol; 2023; 281():191-205. PubMed ID: 37815594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Evolution of Stem Cells, Disease Modeling, and Drug Discovery for Neurological Disorders.
    Pernia C; Tobe BTD; O'Donnell R; Snyder EY
    Stem Cells Dev; 2020 Sep; 29(17):1131-1141. PubMed ID: 32024446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in Patient-Specific Induced Pluripotent Stem Cells Shed Light on Drug Discovery for Amyotrophic Lateral Sclerosis.
    Lee JH; Liu JW; Lin SZ; Harn HJ; Chiou TW
    Cell Transplant; 2018 Sep; 27(9):1301-1312. PubMed ID: 30033758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. iPSC technology--Powerful hand for disease modeling and therapeutic screen.
    Kim C
    BMB Rep; 2015 May; 48(5):256-65. PubMed ID: 25104399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease.
    Wu YY; Chiu FL; Yeh CS; Kuo HC
    Open Biol; 2019 Jan; 9(1):180177. PubMed ID: 30958120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy.
    Liu L; Huang JS; Han C; Zhang GX; Xu XY; Shen Y; Li J; Jiang HY; Lin ZC; Xiong N; Wang T
    Mol Neurobiol; 2016 Dec; 53(10):6698-6708. PubMed ID: 26659595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson's Disease Patients for High-Efficiency Genetic Manipulation and Disease Modeling.
    Hu Z; Pu J; Jiang H; Zhong P; Qiu J; Li F; Wang X; Zhang B; Yan Z; Feng J
    Stem Cells Dev; 2015 Nov; 24(21):2591-604. PubMed ID: 26218671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induced pluripotent stem cells in the study of neurological diseases.
    Saporta MA; Grskovic M; Dimos JT
    Stem Cell Res Ther; 2011 Sep; 2(5):37. PubMed ID: 21936964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating pediatric disorders with induced pluripotent stem cells.
    Durbin MD; Cadar AG; Chun YW; Hong CC
    Pediatr Res; 2018 Oct; 84(4):499-508. PubMed ID: 30065271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons.
    Engle SJ; Blaha L; Kleiman RJ
    Neuron; 2018 Nov; 100(4):783-797. PubMed ID: 30465765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induced pluripotent stem cells and their implication for regenerative medicine.
    Csobonyeiova M; Polak S; Koller J; Danisovic L
    Cell Tissue Bank; 2015 Jun; 16(2):171-80. PubMed ID: 25037593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.